Figure 5.
Survival. OS (A) and LFS (B) for patients receiving the phase 2 dosage of pegIFNα (n = 31).

Survival. OS (A) and LFS (B) for patients receiving the phase 2 dosage of pegIFNα (n = 31).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal